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INTRODUCTION
Marfan syndrome (MFS) is an autosomal dominant connec-
tive tissue disorder usually caused by a mutation in the FBN1 
gene that encodes fibrillin-1. Fibrillin-1 regulates TGF-β sig-
naling, in addition to being a major structural component of 
extracellular matrix microfibrils.1-4 Fibrillin-1 is important in 
multiple organ systems, including the musculoskeletal, ocu-
lar, pulmonary, cardiovascular, and central nervous systems. 
Defects in the cardiovascular system cause death in MFS pa-
tients. Early detection of MFS-related cardiovascular disease 
and prophylactic surgery have been shown to increase life ex-
pectancy up to 60 years old.5-7 The progressive aortic dilatation 
process continues even after aortic surgery, necessitating long-
term medical therapy.8,9 β-blockers are known to slow the rate 
of aortic dilatation by reducing aortic wall stress through their 
negative chronotropic effect. This is the only medication cur-
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Purpose: In this study, we evaluated the long term beneficial effect of Renin-Angiotensin-Aldosterone System (RAAS) blockade 
therapy in treatment of Marfan aortopathy. 
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January 1996 and January 2011. All patients were prescribed β-blockers indefinitely. We compared major aortic events including 
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Results: There were no differences in clinical parameters except for age which was higher in patients with RAAS blockade. In 
group 1, 2 (7%) deaths, 5 (19%) aortic dissections, and 7 (26%) reoperations occurred. In group 2, 3 (5%) deaths, 2 (3%) aortic dis-
sections, and 3 (5%) reoperations occurred. A Kaplan-Meier plot demonstrated improved survival free from major aortic events 
in group 2. On multivariate Cox, RAAS blockade was an independent negative predictor of major aortic events (hazard ratio 0.38, 
95% confidence interval 0.30–0.43, p=0.002). Mean diameter change in descending thoracic and supra-renal abdominal aorta 
was significantly higher in patients without RAAS blockade (p<0.05). 
Conclusion: In MFS patients who underwent ARR, the addition of RAAS blockade to β-blocker was associated with reduction of 
aortic dilatation and clinical events. 
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rently proven in prospective randomized settings to reduce 
aortic dilatation and clinical events, and to improve survival.10 
However, about one out of ten MFS patients who underwent 
aortic surgery experiences re-operation in spite of continuous 
β-blocker therapy.11-13 
Previous researches have shown that propranolol has no 
beneficial effects on elastic fiber fragmentation or aortic wall 
structure, whereas losartan-treated mice show definite im-
provement in both parameters.14 In a non-randomized, retro-
spective study involving 18 pediatric MFS patients who had 
prominent aortic dilatation despite β-blocker therapy, the ad-
dition of an angiotensin receptor blocker (ARB) clearly re-
duced the rate of aortic root dilatation.15 Moreover, angioten-
sin converting enzyme inhibitors (ACEIs) also reduced aortic 
stiffness and dilatation in MFS patients.16,17 However, long-term 
data supporting the efficacy of Renin-Angiotensin-Aldosterone 
System (RAAS) blockade in combination with β-blockers in 
MFS patients who have undergone aortic root replacement is 
lacking. Therefore, we evaluated the long term beneficial effect 
of RAAS blockade therapy in treatment of Marfan aortopathy. 
MATERIALS AND METHODS
Study design and patients 
This was a retrospective study of patients seen at a 2000-bed 
tertiary teaching hospital. The study protocol was approved 
by the Institutional Review Board of Severance Cardiovascu-
lar Hospital (# 4-2013-0524) and was in compliance with the 
Declaration of Helsinki. Between January 1996 and January 
2011, using ICD-9 codes, we identified 143 consecutive pa-
tients diagnosed with MFS (code 759.82) who had undergone 
aortic root replacement (ARR) operation with continuous 
β-blocker therapy after the operation. All patients met the re-
vised Ghent criteria7 and had pathology consistent with me-
dial degeneration. Patients with the diagnosis of Loeys-Dietz 
syndrome or Ehlers-Danlos syndrome were not included in 
this study. Of the 143 patients, we excluded 22 patients with 
prior aortic dissection, 4 patients who underwent ARR under 
the age of 18 years, 11 patients who had a change in β-blocker 
or RAAS blockade prescription status, 2 patients with mental 
retardation (due to the concern of uncertain drug compliance), 
4 patients who were pregnant during follow up, 4 patients with 
more than 1 graft, 3 patients who had overlapping of Dacron 
graft with pulmonary artery (PA) bifurcation, and 3 patients 
with insufficient clinical data. As a result, we enrolled 90 MFS 
patients who underwent ARR in our study. Of these patients, 
62 had Bentall composite graft and 28 had underwent valve-
sparing ARR. 
Clinical data collection
Patient medical records were reviewed for information on pa-
tient age at the time of operation, gender, weight, height, blood 
pressure, heart rate, drug therapy, echocardiographic results 
and computed tomography scan results. Patient databases 
were searched to identify known or putative risk factors for hy-
pertension, dyslipidemia, atrial fibrillation (AF), congestive 
heart failure, congenital heart disease (CHD) other than MFS, 
and smoking status. AF was documented with 12-lead elec-
trocardiography or 24 hr Holter recording. Heart failure was 
defined as satisfying the previously published Framingham 
criteria18 (presence of 2 major or 1 major with 2 minor criteria). 
CHD included repaired or non-cyanotic atrial septal defect, 
ventricular septal defect, tetralogy of Fallot, or coarctation of 
the aorta. We analyzed heart rate and blood pressure, which 
were averaged with more than ten measurements at post-op-
erative outpatient visit. 
Clinical endpoint definition
We evaluated major aortic events including all-cause mortali-
ty, newly developed aortic dissection, and reoperation for re-
current valvular regurgitation or progression distal aorta pa-
thology. Indications for the reoperation consisted of recurrent 
aortic regurgitation of G3 (central jet width/LVOT width=0.50, 
n=1), progressive aneurysmal enlargement of the downstream 
aorta greater than 55 mm in 2 patients, rapidly expanding an-
eurysm (>5 mm in 6 months) in 6 patients, and impending 
aortic rupture in 2 patients. Follow-up was censored after the 
first aortic event. Patients who were alive and aortic event free 
at last follow-up were censored. 
Imaging data collection and analysis
The maximum aortic diameters were measured at five levels 
of the aorta preoperatively; 1) ascending and 2) descending 
thoracic aorta (DTA) at the level of PA bifurcation, 3) aortic 
arch, 4) the mid-section between the diaphragm neck and 
right renal artery ostium, and 5) the inferior mesenteric artery 
(IMA) ostium level. Pulmonary artery bifurcation level corre-
sponded to a level above Dacron graft in all patients. Imaging 
studies included CT scan, trans-esophageal echocardiography, 
magnetic resonance imaging or angiography performed with-
in 3 months before ARR. In case of patients who were evaluat-
ed their aortic dimension by two or more modalities, we se-
lected the maximal diameter. 
Postoperative aortic growth rate of each group was com-
pared in patients who have undergone repeated CT scanning 
after the operation [n=19 (70%) for group 1 vs. n=43 (68%) for 
group 2]. All of these patients took the first scan one week after 
the operation and another follow-up scan at least 1 year after 
operation. We compared the change in the maximal aortic di-
ameter perpendicular to the aortic centerline at 3 levels of the 
aorta. The measurements were obtained from cranial to cau-
dal at the 1) PA bifurcation level, 2) the mid-section between 
the diaphragm neck and right renal artery ostium, and 3) the 
IMA ostium level. The rate of aortic diameter change was cal-
culated by dividing the increment of the aortic maximal diam-
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eter by the time interval on the CT scans. All collected imaging 
data were read in consensus by 2 radiologists who were blind-
ed to the patients’ clinical data. 
Statistical analysis
Continuous variables that were normally distributed were re-
ported as mean±SD, and were compared using Student’s t-
tests for parametric data and Mann-Whitney tests for non-
parametric data. Categorical variables were reported as counts 
(percentages) and compared using chi-squared or Fisher’s exact 
tests. Kaplan-Meier survival curves were plotted for β-blocker-
only patients (group 1) or RAAS blockade-combination pa-
tients (group 2) and compared by means of the log-rank test. 
To identify independent predictor variables, we performed 
multivariate Cox proportional-hazards analysis using the fac-
tors predictive in univariate analysis (p<0.05). The Wilcoxon 
signed rank test was used to compare the rates of aortic diam-
eter change in patients with or without RAAS blockade. A p-
value<0.05 was considered statistically significant. SPSS statis-
tical package (SSPS Inc., Chicago, IL, USA) version 18.0 was 
used to perform all statistical analysis.
RESULTS
Study population and baseline characteristics
Clinical characteristics and echocardiographic parameters 
are presented in Table 1. Of the 90 patients, group 1 patients 
(n=27) had no history of RAAS blockade prescription and 
group 2 patients (n=63) were prescribed β-blocker and RAAS 
blockade concomitantly after ARR. The rationale for prescrip-
tion of RAAS blockade in group 2 patients according to chart 
review are as follows; control of blood pressure (n=22), re-
duced left ventricular systolic function (n=15), attendant’s 
clinical decision (n=14), and not clearly documented on the 
chart (n=12). Of the 90 patients with MFS, 60 patients (67 per-
cent) were male. There were no differences in the clinical 
characteristics of the two groups, except for age at the time of 
ARR. On average, group 2 patients were 4.4 years older than 
group 1 patients (34.8 years vs. 39.2 years; p=0.001). In family 
history, there was no difference in the presence of aortic dis-
section, rupture, sudden death or FBN1 mutation. There were 
no differences in echocardiographic parameters including 
aortic annulus diameter, sinus of Valsalva diameter, or ejection 
fraction. Mean systolic blood pressure and heart rate were not 
different between the two groups. The frequency of other pre-
scription medications, including statins, digoxin, calcium 
channel blockers, and diuretics, were not significantly differ-
ent between the two groups. More detailed demographic data 
that subdivided group 2 into patients with ACEI and ARB are 
shown in Supplementary Table 1 (only online). There was no 
difference in the preoperative aortic dimension between the 
two groups, except for the supra-renal abdominal aorta, which 
was higher in group 2 (Table 2). We evaluated the preopera-
tive aortic dimension within 3 months before ARR in 24 pa-
tients (89%) of group 1 and 58 patients (92%) of group 2. There 
was no difference in the baseline aortic dimensions between 
the groups, except for the supra-renal abdominal aorta level, 
which was higher in patients with RAAS blockade (p=0.002). 
Clinical outcomes
The incidence rates of major aortic events are presented in Ta-
ble 3. During the mean 82±60 months of follow-up, 2 (7%) and 
3 (5%) patients died of cardiac or non-cardiac causes in group 
1 and 2, respectively (p=0.32). The development of aortic dis-
section was significantly higher in group 1 (19% vs. 3%, p=0.02). 
Preoperative maximal diameters of distal aorta of the patients 
who developed new aortic dissection were 45.9 mm; 43.6 mm; 
42.1 mm; 38.6 mm; 36.3 mm in group 1 and 44.2 mm; 37.0 mm 
in group 2, respectively. Of those 7 patients who developed new 
aortic dissection, 2 patients (40%) of group 1 and 1 patient of 
group 2 (50%) had positive family history of aortic dissection. 
The risk of re-operation for recurrent aortic regurgitation or 
distal aortic pathology was also higher in group 1 (p=0.003), 
especially at the aortic arch or DTA level (p=0.01). Conse-
quently, there was a significant difference in the incidence of 
major aortic events between the two groups (p=0.001). In Ka-
plan-Meier analysis, group 2 patients had higher cumulative 
event-free survival than group 1 (p=0.008) (Fig. 1). Clinical 
outcome of patients treated with ACEI or ARB were not differ-
ent, which was significantly better than that of group 1 pa-
tients (Supplementary Fig. 1, only online). We used univariate 
and multivariate Cox regression modeling to test the ability of 
potential baseline risk factors to predict major aortic events. 
Table 4 shows several variables that were associated with a 
higher risk of major aortic events. RAAS blockade therapy, in 
addition to β-blocker was an independent negative predictor 
of major aortic events after adjustment for age, smoking and 
descending thoracic aorta diameter (hazard ratio=0.38, 95% 
confidence interval 0.30–0.43, p=0.002).
Aortic dilatation rate 
A total of 62 patients (69%) had a CT scan performed more 
than twice after ARR: 19 (70%) in group 1 and 43 (68%) in 
group 2. Rates of aortic diameter change measured at 3 posi-
tions are depicted in Fig. 2. At the pulmonary artery bifurcation 
level, the growth rate was 2.7±1.4 mm/yr in group 1 and 1.1±0.7 
mm/yr in group 2 (p<0.001). At the mid-section between the 
diaphragm and the right renal artery ostium level, the growth 
rate was 2.5±1.0 mm/yr in group 1 and 0.9±0.7 mm/yr in group 
2 (p<0.001). There was no significant difference in the rate of 
aortic growth at the IMA ostium level between the groups 
(0.9±0.6 mm/yr in group 1 and 0.8±0.6 mm/yr in group 2, 
p=0.73). 
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DISCUSSION
Although β-blockers have been proven to decrease the rate of 
aortic root dilatation and reduce the risk of clinical events by 
reducing tensile stress on the aorta, the risk of aortic events or 
re-operation is still high. This is particularly true in MFS pa-
Table 1. Baseline Clinical Characteristics and Prescription Status 
Variable Group 1 (n=27) Group 2 (n=63) p value
Female, n (%) 10 (37) 20 (32) 0.53
Age (at aortic root replacement) 34.8±9.3 39.2±12.2 0.001
Risk factors
Hypertension, n (%) 10 (37) 25 (40) 0.92
Dyslipidemia 6 (22) 11 (17) 0.52
Atrial fibrillation 4 (15) 14 (22) 0.47
Congestive heart failure 7 (27) 17 (27) 0.99
Congenital heart disease 1 (4) 6 (10) 0.38
Smoking 19 (71) 37 (59) 0.29
Calendar year of operation 0.83
1996–2000 7 (26) 18 (29)
2001–2005 9 (33) 20 (32)
2006–2011 11 (41) 25 (40)
Family history 
Family history of Marfan syndrome 12 (45) 31 (49) 0.68
Family history of aortic dissection or rupture 11 (39) 28 (44) 0.75
Family history of sudden death 6 (21) 15 (24) 0.88
Presence of casual FBN1 mutation 0.70
Present 9 (32) 18 (28)
Absent 2 (9) 5 (8)
Unknown 16 (59) 40 (64)
Echocardiographic parameters
Mean initial aortic annulus diameter (mm) 33.8±13.0 31.8±10.4 0.51
Mean initial sinus of valsalva diameter (mm) 61.2±13.5 61.4±13.1 0.99
Ejection fraction (%) 56.7±14.0 56.3±11.5 0.89
Aortic insufficiency, n (%) 0.43
Grade 1 5 (18) 6 (10)
Grade 2 4 (15) 6 (10)
Grade 3 10 (37) 23 (36)
Grade 4 8 (30) 28 (44)
Mean blood pressure and heart rate
Systolic blood pressure (mm Hg) 118±11 117±10 0.69
Diastolic blood pressure (mm Hg) 71±10 71±8 0.81
Heart rate (beats/min) 59±10 63±11 0.14
Baseline renal function
Serum creatinine 1.37±0.50 1.26±0.43 0.71
Estimated GFR – mL/min/1.73 m2 68.3±22.7 70.6±21.4 0.87
Estimated GFR rate <60 mL/min/1.73 m2 9 (34) 16 (26) 0.23
Serum potassium – mmol/L 4.5±0.9 4.3±0.7 0.26
β-blocker dose standardized to carvedilol equivalent (mg) 20.8±12.8 13.5±10.1 0.01
Concomitant drug use
Statin 5 (19) 14 (22) 0.68
Digoxin 5 (19) 6 (10) 0.24
Calcium channel blocker 4 (15) 11 (17) 0.63
Diuretic 3 (11) 13 (21) 0.52
GFR, glomerular filtration rate.
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tients who have already undergone aortic operation.19,20 Cur-
rent guidelines on medical treatment after aortic surgery are 
rare and not based on randomized clinical trials.21,22 RAAS 
blockade are attracting much attention in MFS due to their 
ability to modulate excessive TGF-β signaling. There are sev-
eral experimental evidences that supports the superiority of 
ARB, selective angiotensin II receptor type (AT) I blocker, com-
pared with non-selective angiotensin receptor blocking ACEI, 
as the downstream signaling of AT2 ameliorated aneurysm 
progression in rodent Marfan model. However, some contro-
versy exists about the beneficial effect of AT2, as it can also in-
duce vascular smooth muscle cell apoptosis which is prone to 
progression of aneurysm.23 Until now, there is no solid evi-
dence that supports the superior efficacy of ARB compared 
with ACEI, especially in MFS patients who have replaced their 
aortic root. In this study, both ACEIs and ARBs were found to 
be associated with reducing aortic dilatation and major aortic 
events in Marfan aortopathy patients who were previously on 
β-blockers. This phenomenon was independent of the blood 
pressure reduction that can be explained by these molecular 
mechanisms, which are supported by recent evidence in hu-
man and animal studies.24-26 
In addition to its molecular mechanism, RAAS blockade is 
Table 2. Operative Information
 Group 1 (n=27) Group 2 (n=63) p value
Timing of surgery 0.54
Elective, n (%) 23 (85) 50 (79)
Urgent/emergent 4 (15) 13 (21)
Type of aortic root replacement operation 0.74
Bentall operation 19 (70) 42 (67)
Valve-sparing operation 8 (30) 21 (33)
Preoperative maximum aortic dimension (mm)
Patients with available data 21 (78) 58 (92) 
Ascending aorta 31.7±5.4 32.1±3.8 0.71
Aortic arch 30.8±5.8 31.2±5.5 0.65
Descending thoracic aorta 33.5±7.6 34.3±7.3 0.33
Supra-renal abdominal aorta 20.4±4.5 23.1±2.9 0.002
IMA ostium level 21.9±4.4 22.7±3.7 0.41
IMA, inferior mesenteric artery.
Table 3. Major Aortic Events during Follow-Up 
Major aortic event, n (%) Group 1 (n=27) Group 2 (n=63) p value
All-cause mortality 2 (7) 3 (5) 0.32
New aortic dissection  5 (19) 2 (3) 0.02
Re-operation 7 (26) 4 (6) 0.003
Aortic valve 0 1 0.52
Ascending aorta 2 1 0.16
Aortic arch or DTA 4 1 0.01
Abdominal aorta 1 1 0.54
Total 14 (52) 8 (13) 0.001
DTA, descending thoracic aorta. 









β-blocker+RAAS blockade (group 2)
p=0.008
No. at risk
Group 1    27            23              18              15              11              7              5              4
Group 2    63            49              39              27              22             17            10             6
2 4 6
Follow up (years)



















Fig. 1. Kaplan-Meier curves for cumulative survival free from major aortic 
events. Patients without RAAS blockade (group 1) had lower cumulative 
survival free of major aortic events (p=0.008). RAAS, Renin-Angiotensin-
Aldosterone System.
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expected to have beneficial effects on Marfan aortopathy by 
reducing hemodynamic stress. In MFS patients, aortic stiffness 
increases and distensibility decreases over time.27,28 In a previ-
ous study, decreased aortic distensibility was an independent 
predictor of progressive aortic dilatation in MFS patients.29 
Early reflection of the pressure wave from the stiffened periph-
eral arteries increases load on the central arteries and possibly 
increases the risk of aortic rupture.30,31 ARBs and ACEIs have a 
greater effect on aortic stiffness than β-blockers despite their 
similar effects on peripheral blood pressure.32-34 Yetman, et 
al.16 compared the efficacy of enalapril to that of β-blockers in 
a non-randomized, open label study and reported that enala-
pril improved the aortic stiffness and distensibility in MFS pa-
tients and decreased aortic root dilatation and clinical events.
In our study, the concomitant prescription of RAAS block-
ade with β-blocker was negatively correlated with the risk of 
aortic dissection development and re-operation, especially at 
the aortic arch and descending thoracic aorta. The reduction 
in aortic growth rate by RAAS blockade was definite in the 
DTA and abdominal aorta at the supra-renal level, as opposed 
to at the IMA ostium level where there was no difference be-
tween groups. The additive effect of RAAS blockade in MFS 
patients who have undergone ARR might be explained by a re-
duction in shear stress on the central arteries through an im-
provement in aortic stiffness and distensibility, in addition to 
a molecular mechanism. 
Study limitations
There are several limitations to this study. First of all, this was a 
retrospective study conducted at a single center, carrying all the 
limitations of this study design. Dose titration of RAAS blockade 
was almost entirely dependent on clinician’s decision and blood 
pressure measurement. However, the blood pressure measure-
ment did not strictly meet the principle to measure 3 times 
over 3-min interval with constant time gap since last medica-
tion, which could have influenced the outcome. Second, the 
mean age of group 1 patients at the time of ARR was 4.4 years 
younger than group 2 patients, suggesting that the natural 
progression of disease is more rapid in group 1 than in group 
2. On univariate analysis, operation at older ages was nega-
tively associated with major aortic events or re-operation. Al-
though we adjusted for age in the multivariate Cox regression 
analysis, there is still the possibility of selection bias. Third, 
this study covers a relatively long time period, which neces-
sarily includes changes in operation technique and graft pros-
thesis material, both of which could influence clinical results. 
Finally, a histologic study of re-operated patients that might 
show the structural or molecular effects of RAAS blockade on 
the aortas of MFS patients was not performed. A measure-
ment of central pressure, augmentation index, or pulsed wave 
velocity that could explain this result from a hemodynamic 
perspective was not performed in most of patients due to it’s 
retrospective nature. 
To conclude, in MFS patients who underwent ARR, the ad-
dition of RAAS blockade to β-blocker was associated with re-
duction of aortic dilatation and clinical events. This result 
might be explained by improvement in aortic stiffness or dis-
tensibility, as well as inhibition of TGF-β signaling. Further 
evaluation in a prospective setting is needed to confirm the 
benefit. 
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